https://prabadinews.com/
  • October 8, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Foundation Medicine Launches Molecular Residual Disease (MRD) Test for Research Use in Early to Late-Stage Cancers Through its FlexOMx™ Lab

Foundation Medicine Launches Molecular Residual Disease (MRD) Test for Research Use in Early to Late-Stage Cancers Through its FlexOMx™ Lab

BOSTON–(BUSINESS WIRE)–Foundation Medicine adds a tissue-informed whole genome sequencing molecular residual disease test to its portfolio of high-quality testing solutions.

administrator

Related Articles